Non-invasively Quantifying Alveolar Remodeling in Cystic Fibrosis Lung Disease - Formerly fatal, pediatric conditions such as Cystic Fibrosis (CF), have been transformed into chronic conditions. To provide life-long care, subclinical pathologies must be detected before they manifest as significant lung disease when they coincide with normal, age-related lung decline. The clinical standard to measure lung dysfunction is pulmonary function testing (e.g., Forced Expiratory Volume in 1 second, FEV1) but they are insensitive to early and novel pathology. Computed Tomography (CT) identifies lung structural abnormalities, but radiation limits its longitudinal use in children. Further, pathology must be defined relative to health, but lung structure and function change due to normal growth and senescence. The need to safely track emerging, age-dependent pathology is especially pressing in CF, because Highly Effective CFTR Modulator Therapy (HEMT) has increased life expectancy and generated a large population with normal FEV1. To meet this gap, hyperpolarized xenon (HP Xe) MRI is an FDA-approved, radiation- free method to quantify ventilation, gas exchange, and alveolar dimensions. Our long-term goals are to measure lung pathology and predict its trajectory. The current objectives are to establish the prevalence and short-term trajectories of emphysema-like remodelling in people with CF receiving HEMT. Our central hypotheses are that 1) diffusion-weighted Xe MRI can identify early emphysema in CF and 2) the rate of emphysematous remodelling varies with disease severity when HEMT was initiated. Our hypotheses are motivated by strong preliminary data showing Xe MRI can be used to define abnormally small and emphysematously enlarged alveoli in CF. Our rationale is that progressive abnormalities must be quantified early to reduce disease progression. Our central hypotheses will be tested by completing three Specific Aims via a multi-site, multi-MRI platform study: 1) Optimize an efficient, accurate Xe diffusion MRI acquisition, reconstruction and analysis pipeline, 2) Establish normative reference values for lung microstructure using Xe MRI, and 3) Quantify prevalence and trajectory of emphysematous remodelling in people with CF. The proposed research is innovative because it will address key limitations in Xe diffusion MRI, quantify previously inaccessible aspects of lung pathology, and deploy novel imaging tools in CF, where microstructural disease has been neglected. The results will be significant because they provide tools to assess microstructural remodelling in pediatric-onset disorders, including Down syndrome, spontaneous pneumothoraces, anorexia nervosa, premature birth, and CF. This work will have an immediate positive impact by providing normative data to define abnormal lung microstructure and determine the prevalence and trajectory of emphysema in CF. Thus, it will further enable personalized treatment and provide endpoints for therapy trials in the coming era of geriatric Cystic Fibrosis.